CACHET trial

CACHET trial

Comparison of Abciximab Complications with Hirulog (and back-up abciximab) Events Trial. A pilot study comparing abciximab + aspirin + heparin to bivalirudin/hirulog + aspirin + ad hoc abciximab as adjunctive pharmacotherapy for improving outcomes in percutaneous coronary revascularisation.
 
Conclusion
Bivalirubin was better than unfractionated heparin, with fewer bleeding complications.
References in periodicals archive ?
The Medicines Company (NASDAQ:MDCO) announced today that results from the Company's CACHET trial ("Comparison of Abciximab Complications with Hirulog for Ischemic Events") have been published in The American Heart Journal.
We believe that the results of the CACHET trial provide a useful indicator for likely results of our ongoing 6,000-patient REPLACE-2 trial, which has now enrolled more than 4,000 patients," stated David Stack, President and CEO of The Medicines Company.